ClinicalTrials.gg
Not yet recruitingNCT04443543Updated Jun 30, 2020

An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer

A Phase 2 interventional study of Capecitabine (Xeloda) Pharmacogenetic Test Reagents and irinotecan in Rectal Cancer, sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-30.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
222
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies testing oxaliplatin in Rectal Neoplasms — 14 open to participants now, 22 under way, 6 of them phase 3. Oxaliplatin · Rectal Neoplasms.

Planned enrollment
31st of 131
222 · median 58
Started
2020
with 5 others
Phase 2
76 of 152
8 open now
Primary completion
2026-06
later than 12 of 21 live
Registered
135th of 152
by date
Lead sponsor
3 of 152
Fudan University

Among the 152 studies testing oxaliplatin in Rectal Neoplasms, this one is the 31st largest by planned enrollment of the 131 interventional ones that give a count, is one of 6 that started in 2020, is one of 76 in phase 2, reaches primary completion later than 12 of the 21 other live ones, and was the 135th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

14 of the 152 studies testing oxaliplatin in Rectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies testing oxaliplatin in Rectal Neoplasms, or all of them as a file.
02

Study summary

The study is designed to test the hypothesis that the clinical complete response (CCR) rate of patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy will increase after an adaptive-design paradigm, as well as the rate of 2-year organ preservation, recurrence, quality of life, DFS and OS.

Read the detailed description
  1. Primary objective:

    Evaluate the CCR rate of low rectal cancer using adaptive and optimized chemotherapy and radiotherapy strategies (all population and dMMR/MSI-H subgroup)

  2. Secondary objectives:

    2.1 Evaluate the 2-year anal preservation rate, recurrence rate, quality of life, DFS and OS 2.2 Explore the subgroup of patients suitable for observation.

  3. Outline:

Patients after long-course chemoradiation are grouped based on their MSI-H/dMMR status. For patients with MSI-H/dMMR, consolidation immunotherapy of Tislelizumab (BGB-A317) will be assigned. For patients with MSS/pMMR, consolidation chemotherapy will be given according to their tumor response. After completion of consolidation therapy, those who reach clinical complete response will receive organ preservation (watch and wait) strategy in place of radical surgery. During treatment, once local regrowth occurs or poor tumor response, total mesorectal excision (TME) surgery will be performed.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Chemoradiotherapy
  • organ preservation
  • watch and wait
  • irinotecan
  • Tislelizumab
  • capecitabine
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pathological confirmed adenocarcinoma
  • clinical stage T2-4 and/or N+, inappropriate for local excision
  • the distance from anal verge less than 5 cm, or considered inappropriate for anal preservation by surgeons.
  • Strong desire to preserve the anus, able to receive close surveillance for at least 2 years after chemoradiotherapy.
  • without distance
  • aged between 18 to 75 years old.
  • performance status score: 0\~1
  • UGT1A1*28 6/6 or 6/7
  • sign the inform consent

Exclusion criteria

Exclusion Criteria:

  • pregnancy or breast-feeding women
  • serious medical illness
  • difficult to achieve complete response assessed by current evidence: the maximal diameter of tumor >10cm; the maximal diameter of lateral lymph node >2cm; baseline CEA>=100; pathology confirmed signet ring cell carcinoma components; digital rectal examination found that the tumor is peri-narrowed.
  • baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10\^9/L, ≥90g/L, ≥100×10\^9/L, /AST ≤2.5 , Cr≤ 1 ULN
  • DPD deficiency
  • UGT1A1*28 7/7
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
222 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Arm 1 includes patients with MSS/pMMR. In this arm, patients receive consolidation chemotherapy after neoadjuvant chemoradiation (nCRT). The chemotherapy regimens either XELIRI or FOLFIRINOX, and the cycles of chemotherapy depend on patient tumor responses. For patients who reach cCR will enter the "W\&W" cohort and omit radical surgery, while those without cCR will receive radical surgery.

    Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents · Drug: irinotecan · Radiation: IMRT · Drug: Oxaliplatin · Drug: 5Fluorouracil

  • Experimental
    Arm 2

    Arm 2 includes patients with MSI-H/dMMR status. In this arm, patients receive consolidation immunotherapy of 3 cycles of tislelizumab after nCRT. For patients who reach cCR will enter the "W\&W" cohort and omit radical surgery, while those without cCR will receive radical surgery.

    Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents · Drug: irinotecan · Radiation: IMRT · Drug: Tislelizumab

Interventions

06

What researchers measure

Primary outcomes

  1. clinical complete response rate

    After nCRT, the lesions of rectal completely respond. Tumor residue cannot be found by digital rectal examination, endoscopic biopsy and radiology.

    Time frame: two weeks after completion of CRT or consolidation chemotherapy.

Secondary outcomes

  1. 2y-anal preservation rate

    2-year anal preservation rate will be defined as the percentage of patients alive without receiving abdominoperineal resection at 2 years measured from the date of completion of CRT.

    Time frame: 2 years

  2. 2y-local recurrence rate

    2-year local recurrence rate will be defined as the percentage of patients alive developing local recurrence at 2 years measured from the date of completion of CRT.

    Time frame: 2 years

  3. Impact of participants' quality of life

    quality of life is evaluated according to EORTC C-30 questionnare.

    Time frame: 2 years

  4. overall survival

    3-year OS will be defined as the percentage of patients alive at 3 years measured from the date of completion of CRT.

    Time frame: 3 years

07

Study locations

1 site
  • Fudan University Shanghai Cancer Cencer
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2020; primary completion for Jun 2026, 72 months later.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 72 months is above that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2020
First posted
Jun 23, 2020
StartEst.
Jun 22, 2020
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04443543
Lead sponsor
Fudan University
Responsible party
Zhu Ji (principle investigator, Fudan University) — Principal investigator
First posted
Jun 23, 2020
Start date
Jun 22, 2020 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 30, 2020

Study contacts

Ji Zhu
Contact
leo.zhu@126.com
+86-2164175590 ext. 81607

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Fluorouracil · Tislelizumab

Start the discussion